Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1989-06-30
1992-03-31
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
514885, A61K 3702, A61K 4502, A61K 4505
Patent
active
051006642
ABSTRACT:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
McFeeters and Nadler, 20th Meeting of Fed. Amer. Soc. for Exp. Biolopy, Apr. 13-18, (1986), Fed. Proc. 45 (3) 633 (1986).
The Shorter Bergey's Manual of Determinative Bacteriology, Eighth Edition, John G. Holt, Editor, 1977, pp. 135 & 136 published by the Williams & Wilkins Company, Baltimore, Md. U.S.A. 21202.
Anderson Gary A.
Doyle Michael V.
Newell Arthur D.
Nunberg Jack H.
White Thomas J.
Cetus Corporation
Griffin Ronald W.
Halluin Albert P.
McGarrigle Philip L.
LandOfFree
Human IL-2 as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human IL-2 as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human IL-2 as a vaccine adjuvant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257650